NTRBW — Nutriband Inc. Warrant
NASDAQ
$0.50
-$0.02 (-4.31%)
Nutriband Inc. Warrant (NTRBW) common stock listed on NASDAQ. It is led by Gareth Sheridan, based in 121 South Orange Avenue, Orlando, FL, United States, 32801. Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Latest reported NTRBW revenue for 2025-07-31 was $622.5K. Net income was -$2.0M. Revenue was down 6.7% from 2025-04-30 to 2025-07-31.
Use this NTRBW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NTRBW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NTRBW SEC filings page. Lician reads the product cache first so this HTML stays unique to Nutriband Inc. Warrant even when a live quote feed is slow.
About Nutriband Inc. Warrant
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
NTRBW Key Statistics
Market Cap
$0.00M
Volume
3,001
Previous Close
$0.52
Day Range
$0.50 – $0.52
EPS
-$0.99
Revenue
$2.14M
Net Income
-$10.48M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+2.6%
Profit Margin
-489.9%
NTRBW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $2.14M | $2.09M | $2.08M | $1.42M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$10.48M | -$5.49M | -$4.48M | -$6.18M |
| EPS (Diluted) | -$0.99 | -$0.69 | -$0.53 | -$0.80 |
Total Assets
$7.47M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$4.31M
Operating Cash Flow
-$4.63M
Free Cash Flow
$0.00
Nutriband Inc. Warrant Company Information
- Founder, CEO & Director
- Gareth Sheridan
- Headquarters
- 121 South Orange Avenue, Orlando, FL, United States, 32801
- Website
- www.nutriband.com
- Phone
- 407 377 6695
- IPO / Founded
- 2021-10-01